



* Correspondence to: Martin Skott, Department of Urology, Section of Pediatric Urology, Aarhus University Hospital, Aarhus, Denmark.

** Correspondence to: Michele Genech, Department of Paediatric Urology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
martinskott24@gmail.com (M. Skott)
michele.gnech@policlinico.mi.it (M. Genech)
l.thoen@erasmusmc.nl (L.A.'t Hoen)
Uchenna.Kennedy@kispi.uzh.ch (U. Kennedy)
Allon.vanUitert@radboudumc.nl (A. Van Uitert)
zachoual@gmail.com (A. Zachou)
yyuan@mcmaster.ca (Y. Yuan)
j.s.l.t.quaedackers@umcg.nl (J. Quaedackers)
selcuksilay@gmail.com (M.S. Silay)
yazan.rawashdeh@rm.dk (Y.F. Rawashdeh)
berkburgu@gmail.com (B. Burgu)
marco.castagnetti@unipd.it (M. Castagnetti)
fardod.okelly@ucd.ie (F. O'Kelly)
guy.bogaert@uzleuven.be (G. Bogaert)
christian.radmayr@i-med.ac.at (C. Radmayr)

Keywords

Primary obstructive megaureter; Endoscopic management; Pediatric urology; Systematic review

Abbreviations

POM, primary obstructive megaureter; RCT, randomized controlled trials; NRS, non-randomized comparative studies; HUN, hydroureteronephrosis; DRF, differential renal function; UTI, urinary tract infection; PUV, posterior urethral valves; UVJ, ureterovesical junction; ET, endoscopic treatment; UR, ureteral reimplantation; SR, systematic review; UVJO, ureterovesical junction obstruction

Received 16 February 2023
 Revised 23 August 2023
 Accepted 6 September 2023
 Available online xxx

Review Article

Endoscopic dilatation/incision of primary obstructive megaureter. A systematic review. On behalf of the EAU paediatric urology guidelines panel

Martin Skott ^{a,*}, Michele Genech ^{b,**}, Lisette A.'t Hoen ^c, Uchenna Kennedy ^d, Allon Van Uitert ^e, Alexandra Zachou ^f, Yuhong Yuan ^g, Josine Quaedackers ^h, Mesur Selcuk Silay ⁱ, Yazan F. Rawashdeh ^a, Berk Burgu ^j, Marco Castagnetti ^k, Fardod O'Kelly ^l, Guy Bogaert ^m, Christian Radmayr ⁿ

Summary

Introduction

Historically, ureteral reimplantation (UR) has been the gold standard for treatment of primary obstructive megaureter (POM) with declining renal function, worsening obstruction, or recurrent urinary tract infections. In infants, open surgery with reimplantation of a grossly dilated ureter into a small bladder, can be technically challenging with significant morbidity. Therefore, less invasive endoscopic management such as dilatation or incision of the ureter-vesical junction, has emerged as an alternative to reimplantation during the last decades.

Objective

To systematically evaluate the effectivity, safety, and potential benefits of endoscopic treatment (dilatation with or without balloon or incision) of POM in comparison to UR.

Study design

A systematic review was conducted. Randomized controlled trials (RCTs), nonrandomized comparative studies (NRSs), and single-arm case series including a minimum of 20 participants and a mean

follow-up more than 12 months were eligible for inclusion.

Results

Of 504 articles identified, 8 articles including 338 patients were eligible for inclusion (0 RCTs, 1 NRSs, and 7 case series). Age at time of surgery was minimum 15 days to a maximum of 192 months. Indications for endoscopic treatment (ET) included patients with loss of split renal function (>10%) and worsening of hydroureteronephrosis. The studies analysed reported a success rate ranging from 35% to 97%. Success was defined as stabilization of differential renal function without further procedures. A post-operative complication rate of 23–60% was reported (mostly transient haematuria, urinary tract infections and stent migration or intolerance). In 14% of the cases salvage UR following initial ET, was performed due to relapse of symptomatic POM.

Conclusion

Endoscopic treatment for persistent or progressive POM in children is a minimally invasive alternative to UR with a long-term modest success rate. Additionally, it can be performed within a wide age span, with equal success rate and complication rates.

^aDepartment of Urology, Section of Pediatric Urology, Aarhus University Hospital, Aarhus, Denmark

^bDepartment of Paediatric Urology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy

^cDepartment of Pediatric Urology, Erasmus Medical Center, Rotterdam, the Netherlands

^dDepartment of Pediatric Urology, University Children's Hospital Zurich, Switzerland

^eDepartment of Urology, Radboud University Medical Centre, Nijmegen, the Netherlands

^fDepartment of HIV and Sexual Health, Chelsea & Westminster Hospital, London, United Kingdom

^gDepartment of Medicine, McMaster University, Hamilton, ON, Canada

^hDepartment of Urology and Pediatric Urology, University Medical Center Groningen, Rijks University Groningen, Groningen, the Netherlands

ⁱDivision of Pediatric Urology, Department of Urology, Istanbul Biruni University, Istanbul, Turkey

^jDepartment of Pediatric Urology, Ankara University School of Medicine, Ankara, Turkey

^kDepartment of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Padua, Italy

^lDivision of Paediatric Urology, Beacon Hospital, Dublin, Ireland, University College Dublin, Ireland

^mDepartment of Urology, University of Leuven, Leuven, Belgium

ⁿDepartment of Urology, Medical University of Innsbruck, Innsbruck, Austria

<https://doi.org/10.1016/j.jpuro.2023.09.005>

1477-5131/© 2023 The Author(s). Published by Elsevier Ltd on behalf of Journal of Pediatric Urology Company. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Introduction

Primary Obstructive Megaureter (POM) refers to a dilated retro-vesical ureter with a diameter >7 mm from 30 weeks gestational age onwards which warrants postnatal follow-up [1,2].

In the majority of cases POM spontaneously resolves during the first years of life without consequences for renal function [3]. Intervention may be necessary in case of symptomatic children (e.g., recurrent UTI, stone formation), renal function impairment during conservative follow-up and when hydroureteronephrosis (HUN) increases with parenchyma thinning [2].

The classic approach to management is UR performed as open or laparoscopic surgery with an intravesical, extra-vesical or combined technique. It can be technically demanding and associated with significant complications, especially in children younger than 6 months [4–7]. Hence, many surgeons prefer to postpone surgery until >1 year of age, and therefore less-invasive procedures, such as ET, have been proposed as an alternative.

During the last years, studies focusing on long-term effectiveness of ET of POM have been published.

In this systematic review (SR) we present the results of ET (dilatation with or without balloon or incision) of POM, regarding effectivity, safety, and potential benefits, also in comparison to UR.

Evidence acquisition

Types of participants

This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement [8]. A priori protocol was registered at the PROSPERO database (reference CRD42022326752).

Only paediatric patients (children and adolescents <18 years of age), with a uretero-vesical junction obstruction (UVJO) with a loss of differential renal function (DRF) defined as $<45\%$, were included. Our exclusion criteria were: non-primary UVJO (e.g. resulting from a previous endoscopic or surgical procedures or in neurogenic bladder or in PUV-bladder), mean follow-up less than 12 months.

Types of study designs

Randomized controlled trials (RCTs), prospective and retrospective non-randomized comparative studies (NRS's), single-arm case series including a minimum of 20 participants were eligible for inclusion.

Types of interventions

Experimental intervention was ET of UVJO by dilatation with balloon or incision. These interventions could be compared to a control group that underwent open or laparoscopic UR. We did not include studies in which cystoscopy + JJ stent placement was performed as endoscopic management of POM [9]. Although, internal diversion with JJ stent alone for treatment of POM, has been

reported with good outcomes and without the need for further intervention, it has been associated significant high rate of comorbidity [10–12].

Types of outcome measures

The primary outcome for benefits was stabilization of DRF on MAG 3 scan or DMSA without further procedures (endoscopic or surgical). The primary outcome for harms was insufficient result of intervention (progressive loss of function, pain, progressive HUN) with a further need for procedures (endoscopic or surgical). Primary time point was 1 year of follow-up.

The secondary outcomes for benefits were: improvement of out-flow curve on MAG 3 scan, improvement of HUN (distal ureteric diameter, SFU-grade of hydronephrosis, or A-P diameter), resolution of clinical symptoms (such as flank pain), prevention of UTI (long term), prevention of stone formation (long term), length of hospital stay. The secondary outcome for harms were: subsequent secondary procedures requiring anaesthesia (redo-ET, removal of JJ catheter etc.), UTI subsequent to treatment, secondary VUR (de novo VUR and other complications (ureteric perforation, abscess, secondary stenosis of the UVJ).

Search strategy

The literature search was performed using the following databases: EBM Reviews - Cochrane Central Register of Controlled Trials $<December2022>$, Embase <1974 to 2022 December, OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to 2022 December. We used the string terms obstructive megaureter AND endoscopic treatment OR ureteric reimplantation in paediatrics age or synonyms of this. Only English publications were eligible for inclusion. Comprehensive search strategies for each database are provided in Supplement 1.

All abstracts were independently evaluated, using Endnote; by two (double screening) of the four independent reviewers (A.v.U., A.Z., U.K., M.S., M.G.). The disagreements were resolved by interactive discussion and consultation of an independent panel member (L.t.H.). All relevant full texts were evaluated by two (double screening) of the four independent reviewers (A.v.U., A.Z., U.K., M.S., M.G.). The disagreements were resolved by interactive discussion and consultation of an independent panel member (L.t.H.). Outcome data extraction was independently performed by two authors (M.S. and M.G.) using a Data Extraction Form developed a priori with clinical content experts (EAU Paediatric Urology guidelines panel). Any disagreements will be resolved by discussion or by consulting a third review author (L.t.H.).

Assessment of risk of bias

The risk of bias was assessed for each included study by two review authors independently (M.S. and M.G.). Any disagreements were resolved by interactive discussion and consultation of an independent panel member (L.t.H.).

For the comparative studies and case series three issues were considered: the presence of an a priori protocol if the total eligible population was included and recruited consecutively if the primary harm and benefit outcomes were appropriately measured.

A list of the most important potential confounders for efficacy and safety outcomes was developed with clinical content experts (EAU Paediatric Urology guidelines panel) including: age, asymptomatic vs symptomatic, hydro-ureteronephrosis grade of severity, differential renal function, duration of follow-up, it was assessed whether the confounder was considered, balanced and controlled for in analysis.

The risk of bias was considered to be high if the confounder had not been considered and was imbalanced between patients or not corrected during analysis [13].

Data analysis

As valid and sufficiently homogeneous data were not available, we were not able to perform a meta-analysis. We performed a narrative synthesis.

Study characteristics and outcomes from the eligible studies are shown in Table 1 and Table 2, respectively. Regarding the binary/dichotomous/categorical benefit or harm outcomes, odds ratios (OR) were used where available. Mean difference (MD) with 95% confidence intervals (CIs) were used to report the continuous outcomes.

Evidence synthesis

Quantity of evidence identified

The search and selection process of the articles are demonstrated in the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) flow diagram (Fig. 1). A total of 504 abstracts and titles were screened and 22 were retrieved for full text screening. Finally, 8 studies were found eligible, recruiting a total of 338 patients (RCTs: 0, NRSs: 25, Case series: 313). Three hundred nine patients were analysed with 330 renal units included.

Characteristics of the included studies

The baseline characteristics of all included studies are presented in Table 1.

Characteristics of NRS

One NRS, including 25 patients met the inclusion criteria. This retrospective study compares outcomes between high-pressure balloon dilatation of the UVJ and UR with ureteral tapering to treat POM. Ureteral reimplantation was a Cohen's or Leadbetter-Politano neo-ureterocystostomy associated with a Hendren's tapering. Surgery was performed on a combination of clinical, ultrasonographic and functional scan [14].

Characteristics of case series

A total of 7 case series, including 313 patients, were included. All the studies were retrospective paediatric single centre case series from 2007 to 2022 with a recruitment period from 1999 to 2020 [15–21].

Indication for surgery were presence of: worsening of the HUN [18], symptoms [14–17,20,21], loss of DRE [14–17,20,21] described as more than 10% for pre-operative DFR less than 40% in four studies [14,16–18], obstructive curve on MAG3 [15,20].

Endoscopic high-pressure balloon dilatation was performed in six studies under general anaesthesia with appropriate antibiotic prophylaxis [14,16–20]. A paediatric cystoscope (7Fr–9.5F) was introduced to the bladder and a hydrophilic guidewire was negotiated through the UVJ, followed by the dilating balloon. The balloons used were usually semi-compliant dilation catheters with various sizes (2.7–3.1 Fr, 2.5 Fr, 3.1F, 3.4–5.8 Fr etc) from various manufactures, inflated to 12–20 atm for 3–5 min. All dilatations were performed under fluoroscopic guidance. A JJ stent was positioned after the balloon dilatation and left in place for 4–12 weeks [14,16,18,20]. In one study [19], the authors did not use the JJ stent at the end of the procedure and compared the results with a control group that had a stent positioned after dilatation. One author only positioned JJ stent in very few selective cases following dilatation [17].

Kajbafzadeh et al. treated 47 children with an endoscopic endo-ureterotomy, with an incision made at the 6 o'clock using pure cutting current followed by JJ stent left indwelling for one week [21]. Teklali et al. [15] dilated the narrow UVJ under fluoroscopic guidance, with ureteral dilators (6-8Fr) advanced over a guidewire positioned in the ureter. Following removal of the dilator, a JJ stent adapted to the child's age was inserted for 4–6 weeks.

Risk of bias summary for the included studies

Fig. 2 demonstrates the risk of bias (RoB) summary and confounding assessments for the 8 articles. Low risk of attrition bias was present in more than half of the studies, whereas high risk was present for two study [16,20]. None of the studies had an a priori protocol, and the majority were not clear about the criteria of the included eligible population.

There was either a high or an unclear risk for confounders overall, with only one study [15] reporting general low risk of bias for confounder severity. All the studies had a general low or unclear risk for described confounders but high or unclear control for confounders (Fig. 2).

Primary outcomes of included studies

Data from NRS and case series

The primary outcome results of 1 NRS and 7 case series are summarized below and in Table 2.

Table 1 Characteristic of the included studies.

General					N. of patients analysed			N. of patients excluded			N. of Renal Units			Age mean/median Months			FU mean/median Months		
First Author	Journal	Year	Study design	Recruitment period Years	Inclusion criteria	Indications for surgery	ES	IN	CO	ES	IN	CO	ES	IN	CO	ES		IN	CO
Kajbafzadeh J. Endourol 2007	Retrospective Single center	Single arms	1999–2005	POM	Symptoms; Worsening HUN; Loss of renal function; No VUR.		47	47	–	0	0	–	52	52	–	44,4 (1.5–132)	44,4 (1.5–132)	–	39 (14–62)
Garcia-Aparicio J Ped Urol 2013	Retrospective Single center	Comparative	2005–2010	POM; Ureter >10 mm; Obstructive curve on MAG3; No VUR.	NR		25	13	12	0	0	0	25	13	12	–	7 (4–24)	14 (7–84)	36 (24–48) 72 (48–84)
Romero J. Endourol 2014	Retrospective Single center	Single arms	2003–2010	POM; Worsening HUN (retrovesical ureter >10 mm); Impaired renal spilt function with obstructive curve.	Symptoms (febrile UTI, pyeonephrosis); Worsening HUN; Loss of renal function; Obstructive curve.		22	22	–	7	7	–	25	25	–	4.04 (1.6–39)	4.04 (1.6–39)	–	47 (IQR 39,07)
Teklali J Ped Urol 2018	Retrospective Single center	Single arms	2006–2016	POM; Symptoms despite AP and release of preputial adhesions; Retrovesical ureter >10 mm, DRE <35%; No VUR.	Symptoms; Worsening HUN; Loss of renal function; Obstructive curve.		35	35	–	0	0	–	37	37	–	30.6 (2–192)	30.6 (2–192)	–	38 (8–120)
Ortiz Front. Pediatr. 2018	Retrospective Single center	Single arms	2004–2016	POM; Distal ureter >10 mm Worsening HUN Obstructive curve on MAG-3 No VUR	"Febrile UTI despite AP; Worsening in HUN: DRE <40% or DRF reduction >10%."		73	73	–	19	19	–	79	79	–	4 (15°-43,2)° days	4 (15°-43,2)° days	–	67,2 (18–162)
Chiarenza Ped Med Chir 2019	Retrospective Single center	Single arms	2005–2018	POM; Distal ureter >7 mm Worsening HUN Obstructive curve on MAG-3 No VUR.	Symptoms; Worsening HUN; Loss of renal function.		35	35	–	3	3	–	35	35	–	23 (3–66)	23 (3–66)	–	78 (12–168)
Destro Ped Med Chir 2020	Retrospective Single center	Single arms	2012–2018	POM; Retrovesical ureter >10 mm; Drop in DRE; No VUR.	Febrile UTI despite AP; Worsening in HUN: DRE <40% or DRF reduction >10%.		30	30	–	0	0	–	31	31	–	3.6 (0,4–12,2)	3.6 (0,4–12,2)	–	39,6
Faraj J Ped Urol 2022	Retrospective Single center	Single arms	2012–2020	POM; Worsening HUN: Drop in DRE; Symptoms; No VUR.	Symptoms		42	42	–	0	0	–	46	46	–	12,5 (2–128)	12,5 (2–128)	–	35.5 (12–101)

N. = Number; N.R. = Not reported; O = open; E = Endoscopic; ES = Entire Study; IN= Intervention; CO= Control; FU= Follow-up; POM = ; DRE = Differential renal function; VUR= Vesical-Ureteral reflux; HUN= Hydronephrosis; AP = antibiotic prophylaxis; UTI= Urinary tract infection.

Please cite this article as: Skott M et al., Endoscopic dilatation/incision of primary obstructive megaureter. A systematic review. On behalf of the EAU paediatric urology guidelines panel, Journal of Pediatric Urology, <https://doi.org/10.1016/j.jpuro.2023.09.005>

Complication of surgery/interventions

García-Aparicio et al. reported overall minor and major complications in 15 (60%), specifically 12 (92%) for the ET and 3 (25%) for the UR groups.

Minor and major complication in the case series from Teklali et al. Romero et al., Ortiz et al. Destro et al. and Faraj et al. were 15 (43%), 9 (31%), 23 (29%), 7 (23%), 13 (31%) respectively [15,16,18–20]. Two studies did not report the number of complications [17,21].

Overall post-operative complications reported by the included NRS and case series were: stent migration, stent intolerance, UTIs, transient haematuria, pain, persistent UVJO. The most reported complications were UTI's, haematuria and VUR. UTI was seen in 75% of the studies [17,21]. Urinary stone formation was described in only one patient in the Teklali's series and in three by Faraj et al. [15,19].

Faraj et al. [19] reported a significantly higher rate of post-operative complications (severe sepsis requiring urinary diversion, stent migration associated with pain etc) in the group of patients with JJ stent placement after endoscopic balloon dilatation compared to patients without JJ stent. No differences in success rate (defined by absence of further UR) were registered between the two groups.

The reported percentage of de novo VUR was 8% (26/330 renal units) in the current review [14–21]. Of these 26 renal units, 17 cases were managed by sub-ureteral endoscopic bulking therapy, 7 cases by UR and in 2 cases no details about secondary management were noted [14,19]. Three case series reported no incidence of de novo VUR [15,16,21]. Only one author routinely screened for de novo VUR postoperatively with VCUG [14]. Others performed VCUG during follow up only in case of febrile UTI to rule out VUR [17,18,20]. The remaining authors did not specify when, why and whether VCUG was performed during follow up [15,16,19,21].

Intervention not feasible

The most frequent reasons for a non-feasible procedure were the failure of the guidewire to pass through the UVJ reported in 13/24 [18,20,21] and anatomical anomalies (ectopic ureteral implantation, meatal stenosis etc.) in 4/24 patients [15,17] whereas in 7 patients it was not specified [16] and in two studies it was not reported [14,19].

Failure of the treatment

The number of failed procedures that required a ureteral reimplant varied widely between the studies: Teklali et al. 1/35 (3%), Kajbafzadeh et al. 5/47 (11%), Garcia-Aparicio et al. 3/25 (12%), Destro et al. 5/30 (17%), Chiarenza et al. 6/35 (17%), Romero et al. 7/29 (24%), Ortiz et al. 10/79 (13%) and Faraj et al. 9/42 (21%) [14–21]. Chiarenza et al. performed Cohen's ureterocystostomy [17]. None of the other case series reported the method of salvage UR [15,16,18–21]. In the NRS a psoas-hitch-Leadbetter-Politano technique was used in two patients in the UR group as secondary UR [14].

Pre- and post-operative hydronephrosis

Three case series report data about the diameter of the renal pelvis [18–20]. In Romero et al. study population pre-operative median diameter was 18 (12–26) mm and 8 (0–20) mm 18 months after surgery, Ortiz et al. report a pre-operative mean pelvis diameter of 19.2 ± 4.9 mm and 5.2 ± 3.5 mm post-operative 18 months after surgery and Faraj et al. report a median pre-operative diameter of 15 (0–46) mm and post-operative of 9 (0–36) mm.

In the study by García-Aparicio et al., pre-operative major diameter of the renal pelvis was 27 (10–47) mm and post-treatment 0 (0–10) mm in the ET group whereas it was 19 (10–58) mm pre-operative and 9.5 (0–24) mm post-operatively in the UR group.

All studies reporting data about renal pelvis showed an improvement after surgery [14,18–20].

Also, all the studies reporting ureteral diameter showed an improvement after surgery. Pre- and post-operative ureteral diameter was reported by Teklali et al. 16 (10–30) mm and 6 (2–20) mm respectively, by Destro et al. 16 (10–25) mm and 7.9 (2–15) mm respectively, Ortiz et al. report a pre-operative mean diameter of 14.9 ± 2.9 mm and 6.6 ± 6.5 mm post-operative 18 months after surgery and Faraj et al. report a median pre-operative diameter of 15 (6–27) mm and post-operative of 9 (0–30) mm. Romero et al. reported pre-operative diameter 14.2 (11–21) mm and post-operative data from only five patients 8.5 (3–11).

Improvement of the outflow curve on renal scan

Improvement of the out-flow curve on renal scan was found in 57% patients by Teklali et al. and in 69% of renal units in Romero's et al.

Discussion

Principal findings

Treatment success rates were between 35% and 97% in the included case series, whereas the only NRS [14] that compared the outcomes between ET with high-pressure balloon dilatation of the UVJ and UR, presented a success rate of 85% and 92% respectively.

Age at intervention was not uniformly reported, some as mean \pm SD in months [15,16,21] others a median and range in months [14,17–20]. Therefore, no overall average age in months was reported in this SR. A tendency towards a younger age at intervention in the ET group compared to the UR group in the NRS [14] was noted, although not statistically significant.

Some studies evaluated age at intervention [16,17] and/or cystoscopic appearance of the ureteral orifice [16] as predictors for success of treatment. No significant differences in success of ET of POM were found in these subgroups.

Drainage (JJ stent) of the upper urinary tract following dilatation/incision of a narrow UVJ, is suggested for a short period to prevent possible obstruction due to oedema,




Fig. 1 PRISMA flow diagram. PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-analysis.

	Complete outcome data (attrition bias)	Outcome data appropriately measured (attrition bias)	Was a priori Protocol?	Was the total eligible population included?	Was the total eligible population recruited consecutively?	Confounders											
						Hydroureteronephrosis		Asymptomatic vs		Differential renal function		Age		Duration of follow-up			
						Described (yes/no)	Controlled for (yes/no)	Described (yes/no)	Controlled for (yes/no)	Described (yes/no)	Controlled for (yes/no)	Described (yes/no)	Controlled for (yes/no)	Described (yes/no)	Controlled for (yes/no)		
1. Kajbafzadeh 2007	+	+	+	?	?	+	+	+	+	+	+	+	?	+	?		
2. Garcia-Aparicio 2013	+	+	+	?	?	+	+	+	+	+	+	+	?	+	?		
3. Romero 2014	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
4. Teklali 2018	?	?	+	+	?	+	+	+	+	?	?	+	+	+	+		
5. Ortiz 2018	+	+	+	?	?	+	+	+	+	+	+	+	+	+	+		
6. Chiarenza 2019	+	+	+	?	?	+	+	+	+	+	+	+	+	+	?		
7. Destro 2020	+	+	+	?	?	+	+	+	+	+	+	+	+	+	?		
8. Faraj 2022	+	+	+	?	?	+	+	+	+	+	+	+	+	+	+		

Fig. 2 Risk of Bias and Confounders for the 8 studies.

epithelia hyperplasia, or inflammatory cell reaction. However, JJ stent placement has been reported to be associated with morbidity [10]: abdominal pain, haematuria, stent migration or incrustation, urinary tract infections etc. Faraj et al. noted a significantly higher post-operative complication rate in the group of patients with a JJ stent positioned after endoscopic balloon dilatation compared to the group without JJ stents. The two groups being comparable with a demonstrated equal success rate following treatment.

In 2018 by Doudt et al. [9] published a SR, investigating ET of POM and its outcome. They included 12 case series describing 222 patients with 237 obstructed renal units.

Mean age at time of surgery was 24.6 months (range 3–84). All study subjects were either examined by an ultrasound scan of the urinary tract or MAG 3/magnetic resonance urography; some received both. After a single intervention (cystoscopy + balloon dilatation + JJ stent, cystoscopy + ureterotomy + JJ stent or cystoscopy + JJ stent), there was a 69.6% improvement in HUN and a 68.0%

either stable or improved DRF. Success rates were highest in children ≥ 12 months of age (overall 71.8% after a single intervention) compared to infants (overall 61.9% after a single intervention).

Another SR was published by Aiello et al. [22] who included 13 retrospective studies with a total of 324 patients with a median age ranging from 4 months to 7 years. Indications for treatment varied in the different studies, however most studies included patients with increasing dilatation, obstructive patterns on MAG-3 scan, decreased renal function or symptoms. Endoscopic management included endoscopic balloon dilatation or incision of the UVJ usually followed by temporary JJ-stent placement. The overall median follow-up was between 21 months and 10.3 years. Overall success rate reported ranged from 69 to 100%. The complication rate ranged from 0 to 50%. De novo VUR was reported in some of the included studies, with an incidence between 5% and 27%.

The findings in these two SR [9,22] are comparable to the findings of the current SR. As opposed to the other reviews, the current SR did not include studies in which cystoscopy + JJ stent placement was performed as ET of POM [9]. Although, internal diversion with JJ stent alone for treatment of POM, has been reported with decent outcomes and without the need for further intervention, it has been associated with a significantly high rate of comorbidity [10] [–] [12]. Moreover, contrary to Doudt et al. [9] we did not find any differences in terms of success of the ET of POM between patients younger than 1 year and older ones.

Implications for clinical practice

Historically, UR with or without ureteral remodelling has been the gold standard for treatment of progressive or persistent POM. It has stood the test of time, producing excellent and durable result with success rates over 90% in several studies [5,6,23]. In comparison to ET (dilatation with or without balloon or incision), open surgery with reimplantation of a grossly dilated ureter into a small bladder, can be technically challenging with significant morbidity [4–7]. Furthermore, the possible iatrogenic postoperative bladder dysfunction following UR has been reported by several authors [24–26].

A limitation to ET in infants is the risk of not be able to pass the balloon catheter into the obstructed segment of the ureter or failure to pass the paediatric cystoscope into the urethra. In our SR initial failure to perform ET occurred in 7% (24/330) of the obstructed renal units, with a preponderance of cases in the study by Chiarenza et al. [17]. Overall, most of these cases went on to UR.

During follow up, 28 cases (28 renal units) had a secondary balloon dilatation, either at removal of JJ-stent because the ureteral orifice could not accommodate the paediatric cystoscope or as a salvage procedure because of relapse of POM.

Overall, 14% (47/330) of renal units ended up with salvage UR following initial ET, due to relapse of symptomatic POM. In patients undergoing UR the salvage rate (re-do UR) was 17% (2/12) of renal units in the NRS [14] in this SR and in the literature reported to be within 3–5% [5–7,23].

There is concern that manipulation of the ureteral orifice when performing ET of POM, can result in iatrogenic vesicoureteral reflux (VUR). In the current SR, the overall incidence of de novo VUR was 8% (26/330 renal units). Compared to, patients undergoing UR for POM, the incidence of de novo VUR is reported to be between 3 and 13% depending on the surgical technique [5,6,23].

It should however be noted that most of the studies covered in this SR did not routinely screen for VUR [14], with most VCUGs being performed on indication of febrile UTI during follow up [17,18,20] therefore the true incidence of de novo VUR may be higher than what has been reported. In three case series, no events of de novo VUR occurred during follow up. Interestingly, no VCUG was performed in those case series during follow up [15,16,21]. Finally, de novo VUR may in some cases also be transient following ET of POM, and as stated by García-Apericio et al. [27] VCUG should not routinely be performed during follow up, but limited to cases where febrile UTIs are occurring.

Further research

It is imperative that studies with long-term follow-up of children diagnosed with POM treated with endoscopic dilatation/incision be conducted. More importantly, RCTs (endoscopic dilatation/incision vs. UR) providing pre- and postoperative measurement of renal function are needed.

Limitations and strengths

In this SR several strengths and limitations need to be addressed.

First, the quality of evidence from the included studies were average with retrospective case series design, small sample sizes, significant heterogeneity in primary endpoints and short follow-up being common.

Second, selection bias may be another limitation, as only three out of the eight studies clearly stated the use of consecutive patients. It is possible that patients in the remaining three studies [14,16,20] selected for ET had radiographic findings that were more likely to result in improvement or resolution of POM with conservative management alone (i.e., more acceptable DRF or stable HUN).

Third, we may have introduced bias based on language restriction and by excluding single case reports, single cases series less than 20 patients and mean follow-up less than 12 months.

The strength of this SR on the other hand is that it was performed by a group of experts including clinicians and methodologist (EAU Paediatric Urology Guideline Panel) according to PRISMA guidelines with results planned to be incorporated into the upcoming updated of the practice guidelines.

Conclusion

In conclusion, ET (dilatation with or without balloon or incision) for persistent or progressive POM in children is a minimally invasive alternative to UR with a modest success rate. The procedure could not be completed in 10% of the cases and 13% ended up with salvage UR following initial ET,

because of relapse of symptomatic POM. Additionally, ET could be performed within a wide age span (15 days of age to 192 months of age), with equal success and complication rates.

Conflict of interest

None.

Acknowledgements

This systematic review was performed under the auspices of the European Association of Urology and the European Society for Paediatric Urology, Paediatric Urology Guidelines Panel.

References

- [1] Hellström M, Hjälmsås K, Jacobsson B, Jodal U, Odén A. Normal ureteral diameter in infancy and childhood. *Acta Radiol* 1984; 26:433–9. <https://doi.org/10.1177/028418518502600412>.
- [2] Farrugia M-K, Hitchcock R, Radford A, Burki T, Robb A, Murphy F, et al. British Association of Paediatric Urologists consensus statement on the management of the primary obstructive megaureter. *J Pediatr Urol* 2014;10:26–33. <https://doi.org/10.1016/j.jpuro.2013.09.018>.
- [3] Ranawaka R, Hennayake S. Resolution of primary non-refluxing megaureter: an observational study. *J Pediatr Surg* 2013;48:380–3. <https://doi.org/10.1016/j.jpedsurg.2012.11.017>.
- [4] Ossandon F, Romanini MV, Torre M. A modified technique of ureteroplasty for megaureter in children. *J Urol* 2005;174: 1417–20. <https://doi.org/10.1097/01.ju.0000173134.44999.a6>.
- [5] DeFoor W, Minevich E, Reddy P, Polsky E, McGregor A, Wacksman J, et al. Results of tapered ureteral reimplantation for primary megaureter: extravesical versus intravesical approach. *J Urol* 2004;172:1640–3. <https://doi.org/10.1097/01.ju.0000138529.43179.dd>.
- [6] Perdzynski W, Kaliciński ZH. Long-term results after megaureter folding in children. *J Pediatr Surg* 1996;31:1211–7. [https://doi.org/10.1016/s0022-3468\(96\)90234-1](https://doi.org/10.1016/s0022-3468(96)90234-1).
- [7] Mollard P, Foray P, Godoy JLD, Valignat C. Management of primary obstructive megaureter without reflux in neonates. *Eur Urol* 1993;24:505–10. <https://doi.org/10.1159/000474359>.
- [8] Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting Items for systematic reviews and meta-analyses: the PRISMA statement. *Phys Ther* 2009;89:873–80. <https://doi.org/10.1093/ptj/89.9.873>.
- [9] Doudt AD, Pusateri CR, Christman MS. Endoscopic management of primary obstructive megaureter: a systematic review. *J Endourol* 2018;32:482–7. <https://doi.org/10.1089/end.2017.0434>.
- [10] Castagnetti M, Cimador M, Sergio M, Grazia ED. Double-J stent insertion across vesicoureteral junction—is it a valuable initial approach in neonates and infants with severe primary nonrefluxing megaureter? *Urology* 2006;68:870–5. <https://doi.org/10.1016/j.urology.2006.05.052>.
- [11] Carroll D, Chandran H, Joshi A, McCarthy LSL, Parashar K. Endoscopic placement of double-J ureteric stents in children as a treatment for primary obstructive megaureter. *Urol Ann* 2010;2:114–8. <https://doi.org/10.4103/0974-7796.68860>.
- [12] Farrugia M-K, Steinbrecher HA, Malone PS. The utilization of stents in the management of primary obstructive megaureters requiring intervention before 1 year of age. *J Pediatr Urol* 2011;7:198–202. <https://doi.org/10.1016/j.jpuro.2010.04.015>.
- [13] Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovich C, Song F, et al. Evaluating non-randomised intervention studies. *Health Technol Assess* 2003;7:1–173. <https://doi.org/10.3310/hta7270>. iii–x.
- [14] García-Aparicio L, Blázquez-Gómez E, Martín O, Palazón P, Manzanares A, García-Smith N, et al. Use of high-pressure balloon dilatation of the ureterovesical junction instead of ureteral reimplantation to treat primary obstructive megaureter: is it justified? *J Pediatr Urol* 2013;9:1229–33. <https://doi.org/10.1016/j.jpuro.2013.05.019>.
- [15] Teklali Y, Robert Y, Boillot B, Overs C, Piolat C, Rabattu PY. Endoscopic management of primary obstructive megaureter in pediatrics. *J Pediatr Urol* 2018;14:382–7. <https://doi.org/10.1016/j.jpuro.2018.05.027>.
- [16] Destro F, Selvaggio G, Marinoni F, Pansini A, Riccipetioni G. High-pressure balloon dilatation in children: our results in 30 patients with POM and the implications of the cystoscopic evaluation. *La Pediatria Medica E Chir* 2020;42. <https://doi.org/10.4081/pmc.2020.214>.
- [17] Chiarenza SF, Bleve C, Zolpi E, Battagliano F, Fasoli L, Bucci V. Endoscopic balloon dilatation of primary obstructive megaureter: method standardization and predictive prognostic factors. *La Pediatria Medica E Chir* 2019;41. <https://doi.org/10.4081/pmc.2019.219>.
- [18] Ortiz R, Parente A, Perez-Egido L, Burgos L, Angulo JM. Long-term outcomes in primary obstructive megaureter treated by endoscopic balloon dilation. Experience after 100 cases. *Frontiers Pediatrics* 2018;6:275. <https://doi.org/10.3389/fped.2018.00275>.
- [19] Faraj S, Loubersac T, Graveleau A, Alliot H, Camby C, Leclair M-D. Postoperative JJ stent is not necessary after balloon high-pressure endoscopic dilatation of primary obstructive megaureter. *J Pediatr Urol* 2022;18:369.e1–7. <https://doi.org/10.1016/j.jpuro.2022.03.028>.
- [20] Romero RM, Angulo JM, Parente A, Rivas S, Tardáguila AR. Primary obstructive megaureter: the role of high pressure balloon dilation. *J Endourol* 2014;28:517–23. <https://doi.org/10.1089/end.2013.0210>.
- [21] Kajbafzadeh A-M, Payabvash S, Salmasi AH, Arshadi H, Hashemi S-M, Arabian S, et al. Endoureterotomy for treatment of primary obstructive megaureter in children. *J Endourol* 2007;21:743–9. <https://doi.org/10.1089/end.2006.0330>.
- [22] Aiello G, Morlacco A, Bianco M, Soligo M, Meneghesso D, Vidal E, et al. Efficacy and safety of high-pressure balloon dilatation for primary obstructive megaureter in children: a systematic review. *Frontiers Urology* 2022;2: 1042689. <https://doi.org/10.3389/fruro.2022.1042689>.
- [23] Ben-Meir D, McMullin N, Kimber C, Gibikote S, Kongola K, Hutson JM. Reimplantation of obstructive megaureters with and without tailoring. *J Pediatr Urol* 2006;2:178–81. <https://doi.org/10.1016/j.jpuro.2005.05.010>.
- [24] Kort LMO de, Klijn AJ, Uiterwaal CSPM, Jong TPVM de. Ureteral reimplantation in infants and children : effects on bladder function. *J Urol* 2002;167:285–7. [https://doi.org/10.1016/s0022-5347\(05\)65451-1](https://doi.org/10.1016/s0022-5347(05)65451-1).
- [25] Lipski BA, Mitchell ME, Burns MW. Voiding Dysfunction after Bilateral extravesical ureteral reimplantation. *J Urol*

- 1998;159:1019–21. [https://doi.org/10.1016/s0022-5347\(01\)63826-6](https://doi.org/10.1016/s0022-5347(01)63826-6).
- [26] Fung LCT, McLorie GA, Jain U, Khoury AE, Churchill BM. Voiding efficiency after ureteral reimplantation: a comparison of extravesical and intravesical techniques. *J Urol* 1995;153:1972. [https://doi.org/10.1016/s0022-5347\(01\)67381-6](https://doi.org/10.1016/s0022-5347(01)67381-6). —5.
- [27] García-Aparicio L, Blázquez-Gómez E, Haro I de, García-Smith N, Bejarano M, Martín O, et al. Postoperative vesicoureteral reflux after high-pressure balloon dilation of the ureterovesical junction in primary obstructive megaureter. Incidence, management and predisposing factors. *World J Urol* 2015;33:2103–6. <https://doi.org/10.1007/s00345-015-1565-9>.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jpurol.2023.09.005>.